DE69840625D1 - Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis - Google Patents

Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis

Info

Publication number
DE69840625D1
DE69840625D1 DE69840625T DE69840625T DE69840625D1 DE 69840625 D1 DE69840625 D1 DE 69840625D1 DE 69840625 T DE69840625 T DE 69840625T DE 69840625 T DE69840625 T DE 69840625T DE 69840625 D1 DE69840625 D1 DE 69840625D1
Authority
DE
Germany
Prior art keywords
compositions
processes
reaction including
including sepsis
subjective reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840625T
Other languages
English (en)
Inventor
Kenneth L Becker
Jon C White
Eric S Nylen
Richard H Snider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDOCRINOLOGY ASSOCIATES EPC L
Original Assignee
ENDOCRINOLOGY ASSOCIATES EPC L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENDOCRINOLOGY ASSOCIATES EPC L filed Critical ENDOCRINOLOGY ASSOCIATES EPC L
Application granted granted Critical
Publication of DE69840625D1 publication Critical patent/DE69840625D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69840625T 1997-02-03 1998-01-29 Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis Expired - Lifetime DE69840625D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/794,740 US5993811A (en) 1997-02-03 1997-02-03 Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
PCT/US1998/000985 WO1998033524A1 (en) 1997-02-03 1998-01-29 Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis

Publications (1)

Publication Number Publication Date
DE69840625D1 true DE69840625D1 (de) 2009-04-16

Family

ID=25163534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840625T Expired - Lifetime DE69840625D1 (de) 1997-02-03 1998-01-29 Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis

Country Status (8)

Country Link
US (1) US5993811A (de)
EP (1) EP0988054B1 (de)
JP (1) JP2001527529A (de)
AT (1) ATE424218T1 (de)
AU (1) AU739645B2 (de)
CA (1) CA2279517C (de)
DE (1) DE69840625D1 (de)
WO (1) WO1998033524A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
DE50015156D1 (de) * 1999-12-22 2008-06-26 Dade Behring Marburg Gmbh Gegen Procalcitonin gerichtete Antikörper, ihre Herstellung und Verwendung
DE50014159D1 (de) 1999-12-22 2007-04-26 Dade Behring Marburg Gmbh Lösungen von humanem Procalcitonin
AU2001253852A1 (en) * 2000-03-31 2001-10-15 Institut Gustave Roussy Preprocalcitonin as tumor rejection antigen precursor and uses thereof
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
CN1658863A (zh) * 2002-04-08 2005-08-24 武田药品工业株式会社 重症脓毒病预防治疗药物
WO2004005539A1 (en) * 2002-07-05 2004-01-15 The University Of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
DE102007009751A1 (de) * 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
CN101790687A (zh) * 2007-08-03 2010-07-28 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
JP5626537B2 (ja) * 2009-01-15 2014-11-19 アーモンドネット インコーポレーテッドＡｌｍｏｎｄｎｅｔ，Ｉｎｃ． 秘密保持形態においてオンライン使用のためのオフラインプロファイルデータを要求すること
US20120149131A1 (en) * 2009-08-28 2012-06-14 B.R.A.H.M.S Gmbh Procalcitonin for the prognosis of adverse events
ES2601104T3 (es) * 2009-10-13 2017-02-14 B.R.A.H.M.S Gmbh Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio
EP2657707A1 (de) * 2012-04-26 2013-10-30 B.R.A.H.M.S GmbH Biomarkers zur Diagnose, Vorhersage, Beurteilung und Therapiesynkopenschichtung
SI2968443T1 (sl) 2013-03-15 2022-01-31 Protagonist Therapeutics, Inc. Analogi hepcidina in njihova uporaba
US10126305B2 (en) 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
DK3143037T3 (da) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc Alpha4beta7-integrin-thioether-peptidantagonister
JP2017530090A (ja) 2014-07-17 2017-10-12 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
US10328045B2 (en) 2014-09-12 2019-06-25 Children's Medical Center Corporation, Inc. Dietary emulsion formulations and methods for using the same
EP3749345A4 (de) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. Konjugierte hepcidin-mimetika
JP7441955B2 (ja) 2020-01-15 2024-03-01 ヤンセン バイオテツク，インコーポレーテツド インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP2023536463A (ja) * 2020-07-28 2023-08-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体
WO2022109328A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5850213B2 (ja) * 1977-06-20 1983-11-09 株式会社第一ラジオアイソト−プ研究所 カルチトニンの定量法
US4493795A (en) * 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5639671A (en) * 1989-09-18 1997-06-17 Biostar, Inc. Methods for optimizing of an optical assay device
JPH05503098A (ja) * 1989-12-15 1993-05-27 カイロン　コーポレイション セプシスの処理のためのサイトカイン抗体
JP2955082B2 (ja) * 1991-10-11 1999-10-04 大阪瓦斯株式会社 ヒトカルシトニンのｎ末端部分を特異的に認識するモノクローナル抗体
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5660826A (en) * 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP

Also Published As

Publication number Publication date
AU739645B2 (en) 2001-10-18
EP0988054B1 (de) 2009-03-04
EP0988054A4 (de) 2005-01-05
CA2279517A1 (en) 1998-08-06
WO1998033524A1 (en) 1998-08-06
EP0988054A1 (de) 2000-03-29
ATE424218T1 (de) 2009-03-15
AU6030998A (en) 1998-08-25
CA2279517C (en) 2010-05-11
US5993811A (en) 1999-11-30
JP2001527529A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
DE69840625D1 (de) Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis
DE69819311D1 (de) Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
SE9700661D0 (sv) New compounds
SE9801526D0 (sv) New compounds
EP1849478A3 (de) Antagonisten des Entzündungsmediators
ATE115160T1 (de) Biologisch abbaubare polyphosphoester.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
TR199802282T2 (xx) Karbolin t�revleri.
NO20004053D0 (no) Glukokortikoid-selektive antiinflammatoriske midler
IT1129080B (it) Composizione e cartina di prova per la determinazione colorimetrica dell acido ascorbico
KR950700323A (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 아미노아세틸머캅토아세틸아미드 유도체(Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE)
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
NO924719D0 (no) Beleggsammensetning og fremgangsmaate for belegning av metallkveiler ved anvendelse derav
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
SE9401197D0 (sv) Active compounds
SE9602286D0 (sv) New compounds
EA199900876A1 (ru) Фармацевтические композиции против кашля
ATE175998T1 (de) Rekombinierte alkalische phosphatase aus kälberdarm
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
MA23587A1 (fr) Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
MA23588A1 (fr) Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition